A Model that Reproduces Syndromes Associated with Human Multiple Myeloma in Nonirradiated SCID Mice
- 1 February 2000
- journal article
- Published by Wiley in Proceedings of the Society for Experimental Biology and Medicine
- Vol. 223 (2) , 190-197
- https://doi.org/10.1046/j.1525-1373.2000.22326.x
Abstract
A human myeloma line was used to create a model of human multiple myeloma in vivo that would reproduce the pathophysiology of the disease, including the cachexia associated with cancer. Unirradiated severe combined immunodeficient (SCID) mice were used as surrogate hosts for in vivo experiments that allowed the effects of autocrine (human) verus paracrine (murine) cytokines on the development of myeloma to be studied. Serum levels of human paraprotein increased over time and with the number of cells transplanted. Transplanted mice developed major syndromes, cachexia and paralysis (due to invasion of bones by myeloma cells), associated with multiple myeloma. Analyses of serum samples obtained from transplanted mice revealed that when the mice were terminal, total serum protein decreased on average by 20%, whereas serum triglycerides decreased on average by 50%. These data indicate the mice were cachectic, which was confirmed by necropsy. The mice had low but measurable levels of both human and murine interleukin (IL)-6, soluble IL-6 receptor, and murine IL-10 in their sera. The presence of these cytokines and the IL-6 receptor in sera are also characteristics of human myeloma in patients. Since human cells do not respond to murine IL-6, it was possible to demonstrate clearly the importance of autocrine IL-6 in establishing myeloma in situ. By reproducing both the hallmarks of a cancer as well as the accompanying paraneoplastic syndromes, this model should be useful in designing more effective therapies for both the primary cancer as well as the accompanying secondary diseases.Keywords
This publication has 29 references indexed in Scilit:
- Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia.Journal of Clinical Investigation, 1998
- Tumor growth, weight loss and cytokines in SCID miceCancer Letters, 1997
- Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantationZeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Interleukin-6, a new target for therapy in multiple myeloma?Annals of Hematology, 1993
- Anti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivoEuropean Journal of Immunology, 1992
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Hybridoma Growth FactorAnnals of the New York Academy of Sciences, 1989
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988
- A Macrophage-Derived Factor Required by Plasmacytomas for Survival and Proliferation in VitroScience, 1986
- Induction of Plasma-Cell Neoplasms in Strain BALB/c Mice with Mineral Oil and Mineral Oil AdjuvantsNature, 1962